Actinium-225 (225Ac, alpha emitter isotopes that emit α-particles)-lintuzumab is a new approach in AML therapy; it is composed of actinium-225 linked to a humanized anti-CD33 mAb and a low-dose cytarabine (LDAC). This evidence concerns the gene CD33 and acute myeloid leukemia.